Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Zheijang Hisun Nixes Celsion Deal after Drug Fails Trial

publication date: Feb 7, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Zheijang Hisun Pharma will not pursue its option to secure China rights for ThermoDox®, the heat-triggered chemotherapy treatment for liver cancer, from Celsion. As the first part of the process, Hisun paid $5 million toward the option about one month ago. Last week, Celsion announced ThermoDox did not meet its primary endpoint in a global Phase III trial. The two parties will examine the data from the China sites to see if there is any reason to seek approval of the drug in China. More details....

Stock Symbols: (SHA: 600267) (NSDQ: CLSN)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors